Abstract:Background and aim: The aim of prospective study was to determine the prognostic value of combined measures of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and pentraxin 3 (PTX3) according to the culprit-plaque morphology (plaque rupture versus plaque erosion) in relation to the in patients with acute ST-elevated myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention. Methods: A total of 434 patients with STEMI aged ≥18 years who underwent pre-intervention OCT imaging of culprit lesions between March 2017 and March 2019 were enrolled. Finally, 235 patients who meet the inclusion criteria were enrolled and the cohort was divided into 3 groups according to PCSK9 and PTX3 levels: group A: PCSK9 < median and Pentraxin 3 (N = 72/30.6%); group B: PCSK9 ≥ median or Pentraxin 3≥ median (N = 91/38.7%); group C: PCSK9 ≥ median and Pentraxin 3≥ median (N = 72/30.6%). MACEs were defined as a composite of all-cause death, myocardial infarction (MI) recurrence, and ischemic stroke, revascularization and heart failure. Outcomes: During a median follow-up of 2.01 years, 50 patients has occurred MACE. Two-year MACE was higher in group C (23/31.9%) than in group B (16/17.6%) and group A (11/15.3%) (p = 0.028). There was a correlation between PCSK9 and PTX3 (r = 0.302, p < 0.003). In multivariable analysis adjusted for age, gender, risk factors, and serum indexes, being in group C remained independently associated with an increased risk of MACE (hazard ratio [HR]: 2.90; p = 0.010), and group B tended to have higher MACE (HR: 1.76; p = 0.172) compared with group A. Among patients with plaque erosion by OCT, group C was independently associated with an increased risk of MACE (HR: 9.04; p = 0.048) after fully adjustment. However, the significant association was absence among patients with plaque rupture. Conclusion and relevance: This study demonstrated the usefulness of combined measures of PCSK9 and PTX3 to enhance risk stratification in patients with STEMI especially among patients with plaque erosion. Patients with elevation of both PCSK9 and PTX3 had a markedly increased risk of MACE.

Study on the relationship between serum level of Pentraxin 3 and short-term prognosis in patients with acute coronary syndrome

The Study of the Relation Between C-reactive Protein,fibrinogen and Acute Coronary Syndrome

The clinic relevance between acute coronary syndrome and the level of serum matrix metalloproteinase-9

Study on the Relationship between Serum Resistin and Acute Coronary Syndrome and Stable Angina Pectoris

Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction

Relationship Between Serum Concentrations of IL-18, IL-10, IL-6 and Acute Coronary Syndrome

Relationship Between the High-Sensitivity C-reactive Protein,cardiac Troponin I and Severity of Coronary Lesion

Prognostic Value of Plasma Pentraxin-3 Levels in Patients with Stable Coronary Artery Disease after Drug-Eluting Stent Implantation.

Serum pentraxin 3 as a biomarker for prognosis of acute minor stroke due to large artery atherosclerosis

Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure.

Prognostic value of serum pentraxin 3 for intracerebral hemorrhage mortality

Relationships Between Level of Plasma Interleukin-33 and Prognosis in Patients with Acute Coronary Syndrome

Admission Pentraxin-3 Level Predicts Severity of Community-Acquired Pneumonia Independently of Etiology.

Increased Serum Pentraxin-3 Level Predicts Poor Prognosis in Patients with Colorectal Cancer after Curative Surgery, a Cohort Study

Correlation of plasma pentraxin 3 with cardiovascular disease in hemodialysis patients

Pentraxin-3 Is a Strong Biomarker of Sepsis Severity Identification and Predictor of 90-Day Mortality in Intensive Care Units via Sepsis 3.0 Definitions

Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI

Intralesional pentraxin 3 increases with atherosclerotic disease progression, but may protect from thrombosis: Friend or foe?

The potential value of Copeptin and Pentraxin3 for evaluating the severity of coronary stenosis in patients with coronary artery disease

Serum Pentraxin3: Its Relationship with left Ventricular Mass Index and its role as a Predictor for Cardiovascular Mortality in Hemodialysis Patients

Changes and Implication of Peripheral Blood Levels of Matrix Metalloproteases-9 and C-reactive Protein in Patients with Coronary Artery Disease